HomeCompareSPIEF vs MRK

SPIEF vs MRK: Dividend Comparison 2026

SPIEF yields 2000000.00% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SPIEF wins by $4.879226400974806e+39M in total portfolio value
10 years
SPIEF
SPIEF
● Live price
2000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.879226400974806e+39M
Annual income
$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00
Full SPIEF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — SPIEF vs MRK

📍 SPIEF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSPIEFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SPIEF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SPIEF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SPIEF
Annual income on $10K today (after 15% tax)
$170,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, SPIEF beats the other by $4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SPIEF + MRK for your $10,000?

SPIEF: 50%MRK: 50%
100% MRK50/50100% SPIEF
Portfolio after 10yr
$2.439613200487403e+39M
Annual income
$2,439,373,269,665,485,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

SPIEF
Analyst Ratings
1
Buy
Consensus: Buy
Price Target
$7.00
+6999900.0% upside vs current
Range: $7.00 — $7.00
Altman Z
-3.9
Piotroski
4/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SPIEF buys
0
MRK buys
0
No recent congressional trades found for SPIEF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSPIEFMRK
Forward yield2000000.00%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$4.879226400974806e+39M$56.8K
Annual income after 10y$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$9,798.13
Total dividends collected$4.879195005460081e+39M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy
Analyst price target$7.00$128.54

Year-by-year: SPIEF vs MRK ($10,000, DRIP)

YearSPIEF PortfolioSPIEF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$200,010,700$200,000,000.00$11,206$366.19+$200.00MSPIEF
2$3,738,731,768,458$3,738,517,757,009.35$12,650$502.35+$3738731.76MSPIEF
3$65,315,062,866,930,490$65,311,062,423,938,240.00$14,407$694.19+$65315062866.92MSPIEF
4$1,066,400,830,062,625,000,000$1,066,330,942,945,357,500,000.00$16,585$967.82+$1066400830062625.00MSPIEF
5$16,272,182,796,453,826,000,000,000$16,271,041,747,565,660,000,000,000.00$19,342$1,363.89+$16272182796453826560.00MSPIEF
6$232,054,240,113,661,900,000,000,000,000$232,036,828,878,069,680,000,000,000,000.00$22,913$1,947.19+$2.3205424011366188e+23MSPIEF
7$3,092,799,066,104,688,500,000,000,000,000,000$3,092,550,768,067,767,400,000,000,000,000,000.00$27,662$2,823.89+$3.0927990661046884e+27MSPIEF
8$38,524,105,697,352,694,000,000,000,000,000,000,000$38,520,796,402,351,967,000,000,000,000,000,000,000.00$34,159$4,173.35+$3.8524105697352695e+31MSPIEF
9$448,468,826,014,798,700,000,000,000,000,000,000,000,000$448,427,605,221,702,600,000,000,000,000,000,000,000,000.00$43,337$6,308.80+$4.484688260147987e+35MSPIEF
10$4,879,226,400,974,806,000,000,000,000,000,000,000,000,000,000$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$56,776$9,798.13+$4.879226400974806e+39MSPIEF

SPIEF vs MRK: Complete Analysis 2026

SPIEFStock

SPI Energy Co., Ltd. operates as a renewable energy company in North America, Australia, Asia, and Europe. The company offers solar storage and module; renewable energy system solutions to residential and small commercial markets; and EPC services to third party project developers, as well as develops, owns, and operates solar projects that sell electricity to the grid. It also provides commercial electric vehicles, EV charger solutions, electric pickup trucks and scooters, and other EV products. The company was formerly known as Solar Power, Inc. and changed its name to SPI Energy Co., Ltd. in January 2016. SPI Energy Co., Ltd. was founded in 2006 and is headquartered in Sacramento, California.

Full SPIEF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this SPIEF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SPIEF vs SCHDSPIEF vs JEPISPIEF vs OSPIEF vs KOSPIEF vs MAINSPIEF vs JNJSPIEF vs ABBVSPIEF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.